Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer By Ogkologos - June 11, 2025 781 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the OASIS-4 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR No Survival Benefit for Adding Adjuvant Chemotherapy to Endocrine Therapy in... June 15, 2022 Enhancements to NCI’s SEER Program Creating New Research Opportunities August 23, 2018 Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent... November 24, 2025 EMA Recommends Granting a Marketing Authorisation for Pomalidomide Viatris January 17, 2024 Load more HOT NEWS FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative... What People With Breast Cancer and Survivors Should Know About Exercising... Clinics Offering “Mammoglam” Services to Encourage More Women to Get Mammograms Longer PFS in Patients with Advanced Melanoma Treated with TILs than...
